Speakers

Expand/Collapse

Adilia Hormigo
Director Neuro-Oncology Division, Icahn School of Medicine
Mount Sinai & The Tisch Cancer Institute

Adilia earned her MD at Faculdade de Medicina da Universidade de Lisboa, and her PhD at New York University. She completed postgraduate clinical training in Neurology at Cornell University and clinical and research neuro-oncology fellowships at Memorial Sloan-Kettering Cancer Center where she served as faculty. Adilia’s research focuses on developing personalized medicine to treat patients with brain tumors. She uses a multidisciplinary approach that includes neuropathology, bioinformatics, biochemistry and the Cancer Vaccine and Cell Therapy laboratory at the Tisch Cancer Institute to develop a new immunotherapy-based treatment. Mutations in glioblastoma lead to the formation of neoantigens. These neoantigens are not present in normal cells. Her treatment targets those neoantigens to activate the immune system and eliminate the cancer cells. Adilia’s team is also developing new methods to increase drug penetration to the brain and to determine other approaches that will enhance the effect of immunotherapy.

Day One

Wednesday, December 09, 2020

11:30 am | Examine the Absolute Utilization of Vaccine Immunotherapy to Treat Glioblastoma

Antonio Chiocca
Neurosurgeon-in-chief & Chairman
Brigham & Women’s

Dr. Chiocca is the Harvey Cushing Professor of Neurosurgery at Harvard Medical School and is the Chairman Neurosurgery at the Brigham and Women’s Hospital.  He was previously Chairman of the Department of Neurosurgery at the Ohio State University Medical Center.  He has been continuously funded by the NIH since 1996. He has more than 300 peer-reviewed publications, some in journals such as Nature Medicine, Nature Biotechnology, Molecular Cell, and PNAS.  He has elucidated how viruses with specific gene mutations will replicate selectively in tumors with a specific defect in a tumor suppressor pathway. He has also shown how modulation of innate immunity will improve replication of these tumor-selective viruses. More recently, he has elucidated how specific microRNAs (mir128 and mir451) regulate cellular target transcripts to permit tumor cell self-renewal and invasion into brain. He has been PI of three multi-institutional clinical trials of gene-, viral-therapies for malignant gliomas, has been permanent member of NIH study sections (NCI DT and NCI P01-D clinical studies), has been a member of the federal recombinant DNA Advisory Committee (RAC/OBA) and of the NINDS Scientific Advisory Council. In 2013, he was elected Vice-President of the Society for Neuro-Oncology (SNO).  He was President of SNO from 2015-2017.. He is currently President of the American Academy of Neurological Surgery and Member at large of the Society of Neurological Surgery and American Association of Neurological Surgery. He also serves on the scientific advisory board of several foundations (Sontag, American Brain Tumor Association).  He received The Grass Award in 2007, the Farber Award in 2008 and the Bittner Award in 2013.  He was elected to the American Society for Clinical Investigation (2005), is an AAAS fellow (2005) and was also elected to the National Academy of Medicine (formerly Institute of Medicine) in 2014.  He received the Charles B. Wilson Career Achievement Award from the CNS/AANS Section on Tumors in 2018 and the Victor Levin Award for Achievement in neuro-ocnology from SNO in 2018.  He also has served on multiple editorial boards and is the current Tumor Section Editor for Neurosurgery and Associate Editor for Neuro-oncology. He was on the editorial board of Journal of Neurosurgery from 2005 until 2012.

Day Two

Thursday, December 10, 2020

9:00 am | Examine Surgical Immunotherapy Trials Using Genes & Viruses for Brain Tumors

Christophe Quéva
Chief Scientific Officer
Oncorus

Christophe Quéva, Ph.D., is Chief Scientific Officer and Senior Vice President, Research. Christophe is responsible for directing and advancing the company’s development program based on its next-generation immunotherapy platform of oncolytic viruses. An industry veteran, Christophe has nearly two decades’ immuno-oncology experience and successful portfolio-building track record from target identification and development through regulatory approval. Prior to joining Oncorus, Christophe was Chief Scientific Officer at iTeos Therapeutics where his responsibilities included leading the generation of an innovative immuno-oncology portfolio of small molecule and antibody programs. Before iTeos, he held successive senior positions at AstraZeneca, Amgen and Gilead Sciences where he led or supported drug discovery programs for oncology and inflammatory diseases, from target selection to commercial approval for small molecules and biologics.
A holder of five patents and widely published, Christophe trained as a post-doctoral fellow at the Fred Hutchinson Cancer Research Center in Seattle after receiving his Ph.D. in Life and Health Sciences from the University of Lille, France.

Day Two

Thursday, December 10, 2020

10:00 am | The Distinctive Design of ONCR-GBM: A MicroRNA Attenuated Oncolytic HSV for the Treatment of Glioma

James Garner
Chief Executive Officer & Managing Director
Kazia Therapeutics Limited

Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation. He has been responsible for several large-scale international clinical programs, and for numerous product approvals in multiple countries. Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia Therapeutics in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore.  Dr Garner is a member of the Australian Institute of Company Directors.

Day Two

Thursday, December 10, 2020

3:30 pm | Realizing Potential: Taking GDC-0084 Forward in Glioblastoma

1:45 pm | Study PI3K as a Key Target in Glioblastoma

11:00 am | PANEL DISCUSSION: Recognize the Financial Difficulty of Developing Glioblastoma Treatments and Moving Drugs to the Next Phase

Jann Sarkaria
Professor of Radiation Oncology
Mayo Clinic

Jann N. Sarkaria, M.D., is a consultant in the Department of Radiation Oncology at Mayo Clinic in Rochester, Minnesota and holds the academic rank of professor of radiation oncology, Mayo Clinic College of Medicine and Science. Dr. Sarkaria earned his B.S. in biology and chemistry from the University of California at Irvine and his M.D. at the University of California Los Angeles. He completed an internship at the University of Hawaii, followed by a radiation oncology residency at the University of Wisconsin. During residency, he was awarded fellowships from the American Society of Therapeutic Radiology and Oncology and from the National Institutes of Health to support a research fellowship in radiobiology at the Institute for Cancer Research in Sutton, England. He continued his training through a postdoctoral research fellowship in the Department of Oncology at Mayo Clinic. Dr. Sarkaria’s translational neuro-oncology laboratory is focused on developing novel therapeutic strategies for people with glioblastoma (GBM) and brain metastases. Global interests in the lab include understanding the basis of resistance to chemotherapy and radiation, identifying methods to overcome therapy resistance, integration of novel signal transduction inhibitors into conventional therapies for newly diagnosed or recurrent GBM, and use of next-generation sequencing and proteomics to guide individualized therapy for patients with GBM. His research is funded by the National Institute of Neurological Disorders and Stroke and the National Cancer Institute.

Day One

Wednesday, December 09, 2020

12:00 pm | PANEL DISCUSSION: Evaluate the Current Challenges, Approaches and Opportunities in Treating Glioblastoma

Jeffrey Skolnik
Vice President
Inovio Pharmaceuticals

Dr. Skolnik oversees all of Inovio’s cancer immunotherapy programs, as well as those for several infectious diseases. Dr. Skolnik was previously at Tetralogic Pharmaceuticals, where he was Vice President of Clinical Research and later Chief Medical Officer, and oversaw all clinical programs in oncology, infectious diseases and dermatology. He was also a Medical Affairs lead in oncology at GSK and held several positions at AstraZeneca including Senior Director for both early and late stage compounds. Dr. Skolnik is also a practicing pediatric Hematologist-Oncologist, and has published several papers regarding pediatric oncology trial design.

Day One

Wednesday, December 09, 2020

5:15 pm | PANEL DISCUSSION: An Overview of Emerging Therapeutic Targets

2:15 pm | Empower the Immune System to Treat Glioblastoma: DNA as Medicine

Day Two

Thursday, December 10, 2020

5:15 pm | PANEL DISCUSSION: Lessons Learned from Failed and Discontinued Clinical Trials for the Treatment of Glioblastoma

4:45 pm | Clinical Case Study: Inovio’s Innovative Combination Trial

Patrick Wen
Director, Center For Neuro-Oncology
Dana-Farber/Brigham & Women’s Cancer Center

Dr. Patrick Wen is a Professor of Neurology at Harvard Medical School, President of the Society For Neuro-Oncology, Co-PI of thr Adult Brain Tumor Consortium and former Editor-In-Chief of Neuro-Oncology. He received his medical degree from Barts and The London School of Medicine and Dentistry and completed his neurology residency in the Harvard-Longwood Neurology Training Program.

Day One

Wednesday, December 09, 2020

12:00 pm | PANEL DISCUSSION: Evaluate the Current Challenges, Approaches and Opportunities in Treating Glioblastoma

9:00 am | An In-Depth Overview of Current Research Strategies for Glioblastoma & Barriers to Progress

Ranjit S. Bindra
Associate Professor of Therapeutic Radiology
Yale School of Medicine

Dr. Ranjit Bindra is a physician-scientist at the Yale School of Medicine and Co-Director of the Yale Brain Tumor Center. In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and it has received international attention with major clinical implications. Follow-up studies from his group subsequently were published in Nature Genetics, and Nature Communications. Dr. Bindra is now translating this work directly into patients in four phase I/II clinical trials. As a biotech entrepreneur he recently co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment.

Day One

Wednesday, December 09, 2020

5:15 pm | PANEL DISCUSSION: An Overview of Emerging Therapeutic Targets

Day Two

Thursday, December 10, 2020

2:15 pm | Target DDR Pathways in GBM, From Mechanistic Insights to Advances in the Clinic

11:00 am | PANEL DISCUSSION: Recognize the Financial Difficulty of Developing Glioblastoma Treatments and Moving Drugs to the Next Phase

William F. Elmquist
Professor and Director of the Brain Barriers Research Center
University of Minnesota

William F. Elmquist is currently Professor and Director of the Brain Barriers Research Center, at the University of Minnesota, Department of Pharmaceutics.  He received his pharmacy degree at the University of Florida, and Pharm.D. and Ph.D. (pharmacokinetics) from the University of Minnesota.  His research has studied the influence of active efflux transporters in the blood-brain barrier (BBB) on CNS drug distribution.  An important project currently underway is examining the determinants of anticancer drug permeability in the blood-brain barrier to improve the treatment of brain tumors.  Long-term objectives of Dr. Elmquist's research include examining expression and regulation of transport systems in key tissues that influence drug disposition, and how variability in expression, either genetically or environmentally controlled, may contribute to variability in drug response in the patient.  Dr. Elmquist has long been a consultant to the pharmaceutical industry and the NIH, served on many journal editorial boards, and is a Fellow of the American Association of Pharmaceutical Scientists (AAPS).

Day One

Wednesday, December 09, 2020

5:15 pm | PANEL DISCUSSION: An Overview of Emerging Therapeutic Targets

Brian Alexander
Associate Professor of Radiation Oncology, Harvard Medical School & Dana-Farber/ Brigham and Women’s Cancer Center
GBM Agile Global Coalition for Adaptive Research

Dr. Alexander is Chief Medical Officer of Foundation Medicine, Inc. and an Associate Professor of Radiation Oncology at Harvard Medical School and Dana-Farber/Brigham and Women’s Cancer Center. He also founded the Program in Regulatory Science at the Dana-Farber Cancer Institute and is a Member of the Scientific Council of the Harvard/MIT Center for Regulatory Science. Dr. Alexander received his B.A. from Kalamazoo College, M.D. from the University of Michigan Medical School, and M.P.H. from the Harvard School of Public Health. He completed his training in radiation oncology at the Harvard Radiation Oncology Program. Dr. Alexander’s research interests focus on innovations in clinical evidence generation to support the development of therapeutics, biomarkers, and novel endpoints. Dr. Alexander co-authored a book entitled “Diagnostic Test Interpretation and Reasoning Under Uncertainty,” detailing the use of Bayesian approaches to clinical decision-making and is the recipient of the Burroughs-Wellcome Innovations in Regulatory Science Award for his work applying such approaches to clinical trial design. Dr. Alexander was the founding principal investigator of INSIGhT, a multi-institutional genomic biomarker-based Bayesian adaptively randomized trial for patients with glioblastoma. Prior to his faculty appointment at Harvard Medical School, Dr. Alexander served as a White House fellow and Special Assistant to the Secretary of Veterans Affairs. In that role, he helped prepare the VA for the transition of administrations, worked to develop a public reporting system for quality, and served as a health policy advisor to the Secretary. Dr. Alexander organized the standup of the VA’s Coordinating Council on National Health Reform and directed the activities of its multi-team Health Reform Working Group. He was also a member of the Institute of Medicine’s Committee on the Governance and Financing of Graduate Medical Education.

Colin Gerner
President
StacheStrong

Day Two

Thursday, December 10, 2020

9:30 am | The Patient Perspective, Challenges Faced and Uniting our Purpose in the Fight Against GBM

Dave Anderson
Senior Vice President, Research
VBI Vaccines, Inc

Day One

Wednesday, December 09, 2020

2:45 pm | Updated Clinical Results in Recurrent Glioblastoma for VBI1901 - A Therapeutic Vaccine Targeting CMV-Associated Cancers

David Andrews
Co-Founder, Chief Medical Officer
Imvax

Day One

Wednesday, December 09, 2020

4:15 pm | Special Look At Phase 1b Imvax Study to Assess the Safety and Efficacy of IGV-001

Day Two

Thursday, December 10, 2020

5:15 pm | PANEL DISCUSSION: Lessons Learned from Failed and Discontinued Clinical Trials for the Treatment of Glioblastoma

David Reardon
Clinical Director, Center for NeuroOncology
Dana-Farber Cancer Institute

Day One

Wednesday, December 09, 2020

11:00 am | An Exclusive Update on Neoantigen Vaccination for Glioblastoma

Day Two

Thursday, December 10, 2020

5:15 pm | PANEL DISCUSSION: Lessons Learned from Failed and Discontinued Clinical Trials for the Treatment of Glioblastoma

Jill Barnholtz-Sloan
Director of Research Health Analytics and Informatics
University Hospitals

Elizabeth Buck
Executive Vice President, Discovery & Translational Sciences
Black Diamond Therapeutics

Day Two

Thursday, December 10, 2020

11:45 am | Examine BDTX-189 - a Small Molecule Inhibitor Targeting Undrugged Oncogenic Driver Mutations of the ErbB Kinases EGFR & HER2

Jim Connor
Professor of Neuroscience & Anatomy & Vice Chair for Research
Penn State Cancer Institute

Jing Li
Associate Professor
Karmanos Cancer Institute

Day One

Wednesday, December 09, 2020

12:00 pm | PANEL DISCUSSION: Evaluate the Current Challenges, Approaches and Opportunities in Treating Glioblastoma

Linda Liau
Chair of Neurosurgery
UCLA

Day One

Wednesday, December 09, 2020

10:00 am | Optimize the Role of Immunotherapy for Treatment of Glioblastoma

Day Two

Thursday, December 10, 2020

11:00 am | PANEL DISCUSSION: Recognize the Financial Difficulty of Developing Glioblastoma Treatments and Moving Drugs to the Next Phase

Josh Allen
Chief Scientific Officer
Oncoceutics

Day Two

Thursday, December 10, 2020

12:15 pm | Assess the Latest Data & EGFRlow Hypothesis & Trial of Onc201

Josh Rubin
Neuro-Oncologist
Washington University

Justin Lathia
Vice Chair & Associate Professor
Cleveland Clinic

Meredith Moore
Patient
OurBrainBank

Day One

Wednesday, December 09, 2020

9:30 am | I’m Still Here - A Long-Term Survivor’s Perspective

Michael Berens
Professor & Director, Deputy Director of Institutional Initiatives, Head Glioma Research Lab, Search Results
The Translational Genomics Research Institute

Michael Lim
Associate Professor, Neurosurgery, Oncology & Radiation Oncology & Director, Brain Tumor Immunotherapy
John Hopkins Medical Center

Day One

Wednesday, December 09, 2020

1:45 pm | Exhausted T-cells for GBM Immunotherapy: An Exclusive Look at Fresh GBM Clinical Trial Results

12:00 pm | PANEL DISCUSSION: Evaluate the Current Challenges, Approaches and Opportunities in Treating Glioblastoma

Petra Hamerlik
Associate Research Director/Bioscience
AstraZeneca

Day One

Wednesday, December 09, 2020

5:15 pm | PANEL DISCUSSION: An Overview of Emerging Therapeutic Targets

Day Two

Thursday, December 10, 2020

2:45 pm | Determine the Functional Interplay Between Aberrant DNA Repair & Cellular Hierarchies in Glioblastoma

11:00 am | PANEL DISCUSSION: Recognize the Financial Difficulty of Developing Glioblastoma Treatments and Moving Drugs to the Next Phase

Rifaquat Rahman
Radiation Oncology Physician
Harvard Medical School

Robert Dillman
Chief Medical Officer
AiVita

Day One

Wednesday, December 09, 2020

4:45 pm | A Complete Review of Autologous Dendritic Cells Loaded with Antigens from Self-Renewing Autologous Glioblastoma Cells

Day Two

Thursday, December 10, 2020

5:15 pm | PANEL DISCUSSION: Lessons Learned from Failed and Discontinued Clinical Trials for the Treatment of Glioblastoma

Robert Fenstermaker
Chair of Neurosurgery
Roswell Park Comprehensive Cancer Center

Day One

Wednesday, December 09, 2020

3:45 pm | SurVaxM, First-of-its-Kind: A Survivin-Targeted Vaccine for Glioblastoma

Susan Chang
Director, Neuro & Oncology
University of Califorina, San Francisco

Day Two

Thursday, December 10, 2020

5:15 pm | PANEL DISCUSSION: Lessons Learned from Failed and Discontinued Clinical Trials for the Treatment of Glioblastoma